Health
Frost & Sullivan Honors Industry Leaders with Prestigious 2024 Best Practices Awards
Top Innovators Recognized for Outstanding Achievements at Semiannual Awards Gala SAN ANTONIO, Oct. 24, 2024 /PRNewswire/ -- The 2024 Frost & Sullivan Best Practices Awards Gala, hosted at the JW Marriott Tucson Starr Pass Resort in Tucson, AZ, brought together the best in business to celebrate tra...
2024-10-24 22:00
1242
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year,$2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized co...
2024-10-24 21:05
1694
IMG Announces 2024 Leave Your Mark Grant Winners
INDIANAPOLIS, Oct. 24, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is excited to announce the winners of its eighth annual Leave Your Mark Grant. This year, more than 800 organizations and individuals submitte...
2024-10-24 21:00
1096
Innovation at the Forefront: Angel Yeast Shines at FHA 2024
SINGAPORE, Oct. 24, 2024 /PRNewswire/ -- The FHA 2024 exhibition in Singapore,
Asia's largest food and beverage show, is taking place from October 22 to 25,
and is generating significant buzz within the hospitality sector. Angel Yeast
2024-10-24 20:30
5309
Besmile Announces RMB 1 Million Donation to Support Shanghai 9th People's Hospital's Dental Service Development
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- Dental service provider Besmile proudly announces a donation ofRMB 1 million to Shanghai 9th People's Hospital, reinforcing its commitment to enhancing dental service capabilities within the industry. The fund will help elevate the medical facilities to cre...
2024-10-24 20:20
5059
SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...
2024-10-24 20:00
829
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...
2024-10-24 20:00
1145
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter challenges like safety assessments, cost control, and te...
2024-10-24 17:53
879
Botanee & Winona Shines at COSMETIC 360: VOGUE FRANCE, Le Figaro Highlight its Award-Winning Innovations
PARIS, Oct. 24, 2024 /PRNewswire/ -- Winona, a leading cosmeceutical brand in China owned by the Botanee Group, is making its mark on the international stage with groundbreaking plant-based innovations in beauty. Its innovative approach has just earned recognition at COSMETIC 360, the world's lea...
2024-10-24 17:41
5341
The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference Held in Chuxiong, Yunnan Province
CHUXIONG, China, Oct. 24, 2024 /PRNewswire/ -- The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference was held in Chuxiong,Yunnan Province onOctober 21. The event was co-sponsored by the China Association of Chinese...
2024-10-24 15:48
4713
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action,...
2024-10-24 15:15
1774
Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- The 17th "C.C. Tan Life Science Award" ceremony was held inShenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the "C.C. Tan Life Science Industrialization Award". C.C. Tan Life Science Award has th...
2024-10-24 13:16
4614
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cance...
2024-10-24 12:42
1448
J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held inBarcelona, Spain, from October 23-25, 2024. The ...
2024-10-24 10:45
1369
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA ...
2024-10-24 10:00
2040
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation
HMI-115 has demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 50% Most of the patients reported normal menstrual periods No typical peri-menopausal symptoms were re...
2024-10-24 08:08
3747
Lycored Introduces Lycomato⁶ ™ Beadlets, Expanding Applications and Branding for Flagship Wellness Extract
BRANCHBURG, N.J., Oct. 24, 2024 /PRNewswire/ -- Lycored, the global leader in naturally derived carotenoids for food, beverage, and dietary supplement products, has launched Lycomato6 ™ Beadlets 5%—a new delivery format for their premier anti-inflammaging solution. This release comes at the same ...
2024-10-24 08:00
1340
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
MELBOURNE, Australia, Oct. 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of g...
2024-10-24 06:02
1483
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
* The first and only lipolytic injectable for large area – CBL-514's last Phase2b study has been completed * Both CBL-514 Phase 2b studies used efficacy assessment tools, AFRS and MRI, in accordance with the U.S. FDA recommendation * CBL-514 Pivotal Phase 3 study is expected to initiate subj...
2024-10-24 01:42
1520
CorDx Selects MasterControl to Streamline Life Science Quality and Manufacturing Processes Globally
IVD leader adopts MasterControl Qx and Mx platforms to ensure regulatory compliance acrossChina, the US and more. SINGAPORE, Oct. 23, 2024 /PRNewswire/ -- MasterControl announced today that CorDx Inc., the global diagnostics company and leader in IVD research and development, has chosen MasterCo...
2024-10-23 23:17
1382
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8703
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5845
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5183